Law360 (June 17, 2021, 4:57 PM EDT) -- Cancer-focused Lyell Immunopharma Inc. went public Thursday after raising $425 million, the largest of four IPOs totaling $847 million that also included a gene-editing biotechnology firm, an online marketplace for biospecimens and a real estate investment trust, guided by seven firms.
South San Francisco-based Lyell, advised by Cooley LLP, sold 25 million shares at $17 each, within its stated range of $16 to $18. Venture-backed Lyell is developing therapies based on T cells — a type of white blood cell that fights infection — intended to cure patients with solid tumors.
Gene-editing biotechnology firm Verve Therapeutics Inc., advised by WilmerHale, sold...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!